Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 24 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

54%

13 trials in Phase 3/4

Results Transparency

13%

2 of 16 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 3
11(47.8%)
Phase 2
5(21.7%)
Phase 1
3(13.0%)
Phase 4
2(8.7%)
N/A
2(8.7%)
23Total
Phase 3(11)
Phase 2(5)
Phase 1(3)
Phase 4(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials
NCT05262010Phase 3Recruiting

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

Role: collaborator

NCT01512706Phase 2Completed

A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants

Role: collaborator

NCT03614702Phase 3Completed

Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV

Role: collaborator

NCT01391494Phase 1Completed

A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants

Role: collaborator

NCT01569581Phase 3Completed

A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children

Role: collaborator

NCT01510366Phase 3Completed

The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)

Role: collaborator

NCT02231632Phase 2Completed

The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)

Role: collaborator

NCT06041061Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

Role: collaborator

NCT02740777Phase 2Completed

Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females

Role: collaborator

NCT02733068Phase 3Completed

A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

Role: collaborator

NCT04436133Phase 2Completed

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

Role: collaborator

NCT04083196Phase 1Completed

A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

Role: collaborator

NCT02203357Phase 4Completed

A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults

Role: collaborator

NCT03821441Phase 3Unknown

Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine

Role: collaborator

NCT01979900Phase 3Completed

Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis

Role: collaborator

NCT01722552Not ApplicableCompleted

China Adherence Through Technology Study

Role: collaborator

NCT02878291Phase 1Unknown

Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Role: collaborator

NCT01056705Phase 2Completed

The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)

Role: collaborator

NCT01892228Not ApplicableUnknown

Pilot Study of Immediate HIV Treatment in Guangxi, China

Role: collaborator

NCT02285036Phase 3Completed

Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children

Role: collaborator